GlassScriptPhysician profile
Terie Guffey
NPI 1720744188
$3,111.52
in general payments reported to CMS, 2019-2025
25 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.98 · 2022: $1,307 · 2023: $1,341 · 2024: $222 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $827.00 | 2022-2025 | |
| Intra-Sana Laboratories | $332.65 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.08 | 2022-2024 | Xifaxan, Trulance |
| Ardelyx, INC. | $240.93 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $230.56 | 2021-2023 | Entyvio |
| Novartis Pharmaceuticals Corporation | $145.20 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $111.94 | 2022-2023 | Linzess |
| Qol Medical, LLC | $110.48 | 2022-2023 | Sucraid |
| Pharmacyclics LLC, An Abbvie Company | $106.83 | 2022-2023 | Imbruvica |
| Genzyme Corporation | $98.40 | 2022-2023 | |
| Redhill Biopharma INC. | $80.07 | 2021-2022 | |
| Janssen Biotech, INC. | $78.82 | 2022-2023 | Stelara |
| Phathom Pharmaceuticals, INC. | $65.32 | 2025 | Voquezna |
| Pfizer INC. | $63.66 | 2022-2024 | |
| Evoke Pharma, INC. | $63.11 | 2022-2023 | Gimoti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $54.21 | 2022-2024 | Stelara |
| Nestle Healthcare Nutrition INC. | $52.77 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $33.05 | 2023 | Dupixent |
| Celgene Corporation | $31.47 | 2022-2024 | Zeposia |
| Novo Nordisk INC | $21.19 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $17.86 | 2023 | Bylvay |
| Gilead Sciences, INC. | $16.85 | 2023 | |
| Axonics, INC. | $16.55 | 2024 | Axonics |
| Braintree Laboratories, INC. | $15.26 | 2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $14.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terie Guffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.